Market capitalization | $4.34b |
Enterprise Value | $4.45b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 7.08 |
P/S ratio (TTM) P/S ratio | 6.90 |
P/B ratio (TTM) P/B ratio | 16.40 |
Revenue growth (TTM) Revenue growth | 240.74% |
Revenue (TTM) Revenue | $628.79m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
18 Analysts have issued a Apellis Pharmaceuticals, Inc. forecast:
18 Analysts have issued a Apellis Pharmaceuticals, Inc. forecast:
Dec '23 | |
Current assets | 766 766 |
Fixed assets | 22 22 |
Total Assets | 789 789 |
Dec '23 | |
Equity | 195 195 |
Debt capital | 594 594 |
Total Capital | 789 789 |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
Head office | United States |
CEO | Cedric Francois |
Employees | 706 |
Founded | 2009 |
Website | www.apellis.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.